Table 2:

Univariate Analysis of Predictors for Progression-Free Survival

Variable		HR (95% CI)	p-value
Age		1.01 (0.96–1.06)	0.70
Sex			0.76
	Male	Ref.
	Female	0.87 (0.36–2.13)
ECOG performance status			0.62
	0	Ref.
	1	1.25 (0.52–3.01)
Stage			0.30
	IIIB	Ref.
	IIIA	0.38 (0.11–1.35)
	IIIC	1.02 (0.36–2.92)
N-Stage			0.80
	N0-N2	Ref.
	N3	1.12 (0.46–2.69)
T-Stage			0.33
	T0-T2	Ref.
	T3-T4	1.55 (0.63–3.81)
Programmed death-ligand 1 (PD-L1) expression			0.38
	< 1%	Ref.
	≥ 1%	0.64 (0.24–1.72)
TMB (mt/Mb)			0.34
	< 8.8	Ref.
	≥ 8.8	1.69 (0.58–4.90)
Time to Durvalumab		0.68 (0.40–1.17)	0.17
Grade ≥ 2 Pneumonitis			0.84
	No	Ref.
	Yes	0.89 (0.30–2.67)